NCT06256562CompletedPhase 2
A Study of GZR18 Injection in Obese/Overweight Patients
A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients
Source: ClinicalTrials.gov · Last updated 1 Oct 2025
Brief summary (registry, in English)
This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 340 (actual)
- First submitted
- 5 Feb 2024
- Start date
- 8 Jun 2023
- Primary completion date
- 5 Jun 2024
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Diseases
- Obesity
- NCT number
- NCT06256562
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 340
- From 8 Jun 2023 to the primary completion date, 5 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion Criteria:
- Male or female aged 18-75 years (inclusive).
- Obese subjects (BMI≥28 kg/m2), Or overweight subjects (24 kg/m2≤BMI\<28 kg/m2) with at least one comorbidity.
- Able to understand the procedures and methods in this study; willing and able to maintain a stable diet and exercise lifestyle during the research period, and willing to sign the ICF voluntarily.
- Exclusion Criteria:
- Limb deformities or defects affecting height and body weight measurement.
- Pregnant or lactating women, men or women of reproductive potential unwilling to use contraception throughout the study and for 6 months after the last dose of investigational drug.
- History of drug abuse within 1 year before screening, or positive results in drug abuse screening during screening or before randomization.
- Alcohol abuse history within 6 months prior to screening.
- Subjects who are known or suspected to be allergic to GLP-1 drugs or excipients.
- Subjects with an absolute weight change greater than 5.0% due to any reason within the 3 months prior to screening.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gan & Lee Pharmaceuticals Co., Ltd Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
- Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.Signal Transduct Target Ther · 2026 · PMID 41760612
This page is information, not medical advice. Discuss any trial with your doctor.